mProX™ Human RIPK2 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Kinase Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human RIPK2 Stable Cell Line (S01YF-1023-PY86). Click the button above to contact us or submit your feedback about this product.
Skyler Garcia (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Cameron Johnson (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 Inhibition of 786-O cell proliferation was achieved through the knockdown of RIPK2.
The assessment of cell proliferation ability following RIPK2 knockdown was carried out through the utilization of the colony formation assay. It was observed that a significant delay in colony formation capacity was achieved with the reduction in RIPK2 expression.
Ref: Li, Diangeng, et al. "RIPK2 is an unfavorable prognosis marker and a potential therapeutic target in human kidney renal clear cell carcinoma." Aging (Albany NY) 13.7 (2021): 10450.
Pubmed: 33790054
DOI: 10.18632/aging.202808
Research Highlights
Holubekova, Veronika. et al. "Differential gene expression of immunity and inflammation genes in colorectal cancer using targeted RNA sequencing." Frontiers in oncology, 2023.
In recent years, colorectal cancer (CRC) has been recognized as a complex and diverse disease characterized by molecular alterations such as driver mutations and gene methylations. The tumor microenvironment (TME) plays a crucial role in the development and progression of CRC, and is heavily influenced by the presence of immune cells with both pro- and anti-tumor effects. Investigating the interactions between the immune system (IS) and the TME is vital for the development of effective immunotherapeutic strategies for CRC. The focus of our study was to analyze the expression profiles of inflammatory and immune-related genes to identify abnormal signaling pathways involved in the development of CRC, its metastatic potential, and the presence of mutations in the Kirsten rat sarcoma virus (KRAS) gene.
Holubekova, Veronika. et al. "Differential gene expression of immunity and inflammation genes in colorectal cancer using targeted RNA sequencing." Frontiers in oncology, 2023.
Pubmed:
37869102
DOI:
10.3389/fonc.2023.1206482
Rivoal, Morgane. et al. "Receptor Interacting Ser/Thr-Protein Kinase 2 as a New Therapeutic Target." Journal of medicinal chemistry, 2023.
The receptor interacting serine/threonine protein kinase 2 (RIPK2) is a vital downstream signaling molecule involved in the activation of innate immune receptors, such as NOD-like receptors (NOD1 and NOD2). The recognition of pathogen-associated molecular pattern proteins by NOD1/2 results in their interaction with RIPK2. This interaction triggers the release of pro-inflammatory cytokines by activating the NF-κB and MAPK pathways. In light of its crucial role in intracellular signal transduction, RIPK2 has emerged as a potential therapeutic target for various conditions such as inflammatory diseases and cancer. This Perspective provides an overview of the mechanisms underlying RIPK2 function, its involvement in various diseases, currently available RIPK2 inhibitors, therapeutic strategies, challenges, and future prospects.
Rivoal, Morgane. et al. "Receptor Interacting Ser/Thr-Protein Kinase 2 as a New Therapeutic Target." Journal of medicinal chemistry, 2023.
Pubmed:
37857324
DOI:
10.1021/acs.jmedchem.3c00593
